• LAST PRICE
    41.6000
  • TODAY'S CHANGE (%)
    Trending Up1.3200 (3.2771%)
  • Bid / Lots
    41.5100/ 2
  • Ask / Lots
    41.7000/ 2
  • Open / Previous Close
    41.0900 / 40.2800
  • Day Range
    Low 40.8915
    High 42.8700
  • 52 Week Range
    Low 30.7550
    High 58.0000
  • Volume
    59,903
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 40.26
TimeVolumeLEGN
09:32 ET392941.81
09:34 ET59841.93
09:36 ET272742.34
09:38 ET80042.34
09:39 ET89142.41
09:41 ET175242.69
09:43 ET92042.86
09:45 ET837542.33
09:48 ET170042.36
09:50 ET79842.29
09:52 ET127942.085
09:54 ET180042.165
09:56 ET30042.175
09:57 ET140042.23
09:59 ET191042.12
10:01 ET50041.94
10:03 ET126042.03
10:06 ET220041.75
10:08 ET190041.46
10:10 ET150241.53
10:12 ET110041.635
10:14 ET299641.5692
10:15 ET120041.59
10:17 ET145541.585
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesLEGN
Legend Biotech Corp
6.5B
-17.8x
---
United StatesAPLS
Apellis Pharmaceuticals Inc
6.5B
-9.2x
---
United StatesASND
Ascendis Pharma A/S
5.6B
-15.8x
---
United StatesKRTX
Karuna Therapeutics Inc
7.4B
-34.3x
---
United StatesCYTK
Cytokinetics Inc
4.5B
-19.7x
---
United StatesGBT
Global Blood Therapeutics Inc
4.6B
-13.7x
---
As of 2022-10-04

Company Information

Legend Biotech Corporation is a global, clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). It has a portfolio of early stage autologous product candidates targeting various cancers, including, gastric cancer, and T cell Lymphoma (TCL), both of which are in investigator-initiated phase I clinical trials. It is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of Non-Hodgkins Lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), and acute lymphoblastic leukemia (ALL). It also has several allogeneic platforms under development targeting BCMA.

Contact Information

Headquarters
2101 Cottontail LaneSOMERSET, NJ, United States 08873
Phone
732-317-5050
Fax
---

Executives

Chairman of the Board
Fangliang Zhang
Chief Executive Officer, Director
Ying Huang
Chief Financial Officer
Lori Macomber
Senior Vice President - Global Business Development
Meeta Chatterjee
Senior Vice President - Global Head of Research and Early Development
Guowei Fang

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$6.5B
Revenue (TTM)
$116.9M
Shares Outstanding
167.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-2.34
Book Value
$3.06
P/E Ratio
-17.8x
Price/Sales (TTM)
55.5
Price/Cash Flow (TTM)
---
Operating Margin
-314.67%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.